In cancer studies the disease natural history process is often observed only at a fixed, random point of diagnosis (a survival time), leading to a current status observation (Sun (2006) . The statistical analysis of interval-censored failure time data. Berlin: Springer.) representing a surrogate (a mark) (Jacobsen (2006) . Point process theory and applications: marked point and piecewise deterministic processes. Basel: Birkhauser.) attached to the observed survival time. Examples include time to recurrence and stage (local vs. metastatic). We study a simple model that provides insights into the relationship between the observed marked endpoint and the latent disease natural history leading to it. A semiparametric regression model is developed to assess the covariate effects on the observed marked endpoint explained by a latent disease process. The proposed semiparametric regression model can be represented as a transformation model in terms of mark-specific hazards, induced by a process-based mixed effect. Large-sample properties of the proposed estimators are established. The methodology is illustrated by Monte Carlo simulation studies, and an application to a randomized clinical trial of adjuvant therapy for breast cancer.
INTRODUCTION
In cancer studies, understanding the disease natural history and its manifestation through the observed survival phenotype is essential for the design of optimal treatment strategies. Cancer endpoints are typically measured at an observed event and represent a time-to-event and a cross-sectional surrogate of the disease natural history (mark) measured at the event. It is crucial to elucidate the relationship between the marked survival phenotype and the latent disease natural history process, and understand what can be learned from the observed data. We study time to cancer recurrence and recurrence site (local or distant) as an application.
C. HU AND A. TSODIKOV
In Section 2.2 we put the developed model in perspective and discuss its special cases and relationship with other approaches that can potentially be used with marked survival endpoints (Huang and Louis, 1998) . They include frailty models (Duchateau and Janssen, 2008) , competing risks (Kalbfleisch and Prentice, 2002) , multistate models (Andersen and Keiding, 2002) , and current status analysis (Kimmel and Flehinger, 1991) . While any survival response with a discrete mark can technically be cast as a (dependent) competing risks problem, traditional approaches such as crude hazards or latent failure times (Fine and Gray, 1999; Chen, 2010; Kalbfleisch and Prentice, 2002) pursue convenience models that cannot be mapped to disease-specific processes. Thus, they may fail to provide clinically important predictions, such as, a prediction of the (unobserved) time of onset of metastases in a patient observed with a certain phenotype at time point t (see Section 5).
In this paper we recognize that a disease history mark measured at the survival event represents a snapshot of a disease progression process leading to the survival event. The model for the mark variables is then mechanistic in nature and depends on the latent association between the disease progression process and the survival time affected by it. Therapeutic interventions and prognostic factors can affect the outcomes directly and through the latent disease process. Understanding this relationship may help us design optimal therapy regimen by targeting the latent process.
Asymptotic properties are established using marked point processes (Jacobsen, 2006) , empirical processes (Kosorok, 2008) and martingale theory (Andersen and others, 1993) . We assess the finite-sample properties of proposed estimators as well as provide a comparison with other approaches, and apply the proposed methods to a randomized clinical trial of adjuvant therapy for breast cancer.
STATISTICAL FRAMEWORK

Model
Consider the response as a random vector (T * , S * ) consisting of a time-to-event T * (diagnosis of cancer recurrence), and a mark S * representing a state of the latent random process S(t) measured at t = T * . In this paper we assume the mark to be binary leading to S being an indicator process S(t) = I (U < t), where the latent random variable U represents a latent stage transition time such as onset of detectable metastases. We distinguish the point T * when metastases are observed (when S * = 1), and the point U when metastases become potentially observable if a recurrence occurs.
Consider a non-parametrically specified baseline cumulative hazard function H (t) (hazard function h(t)) that heuristically summarizes the tumor growth pattern driving the hazard functions for times to various disease progression events driven by tumor growth (See Section 2.2 for details). We use a conditional specification of the joint distribution of (T * , S * , U ) as
where (t) , μ = e β μ , and β = (β η , β θ , β μ ) is the combined vector of regression coefficients. We omit covariates Z as an argument and treat them as time-independent for brevity. An extension to the external time-dependent setting (Kalbfleisch and Prentice, 2002, Section 6. 3) is straightforward. The predictor η models covariate effects on the time U (onset of metastases, an unobserved event when detectable metastases occur). The predictor θ models covariate effects on the time T * (diagnosis of recurrence). The predictor μ may be interpreted
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515 as a dependence measure between the latent disease natural history U and the observed time-to-event T * , modeling how the risk of the observed event is accelerated by the onset of the latent event.
Let G be the survival function of the time to recurrence diagnosis T * , and f (t, S * = s), (s = 0, 1) be the two sub-distribution (crude) probability density functions (pdf 's). Elaborating further on the model quantities (see Section B of supplementary material), we have 2) and the corresponding mark-specific hazards as H (t) ; β|Z i ), and β, Z are incorporated into θ, η, μ. The model presented above is based on a nested hierarchical Cox PH model, one for U and one for T * with U being an internal time-dependent covariate. Alternatively, it can be viewed as an illness-death model (See Section A of supplementary material).
Model assumptions and special cases
Model assumptions. Suppose the total tumor volume in the body may be modeled as v(t). Bartoszynski and others (2001) and later Hanin and others (2006) argued that the hazard of tumor diagnosis λ 1 and the intensity of tumor's shedding of metastases λ 2 (a non-homogeneous Poisson process) are proportional to some power of tumor size v(t), i.e. λ i (t) = c i v γ i (t), where i = 1, 2 for diagnosis and metastases, respectively. Events whose hazard admits a specification based on the current value of a driving process ν i (t) = v γ i (t) are called quantal (Bartoszynski and others, 2001 ). Klein and Bartoczynski (1991) estimated that γ i = 1 provided the best fit to breast cancer data. Since we also use breast cancer data in the application, we will proceed from the proportional relationship λ i (t) = c i v(t). This comes without loss of generality, as a power function in the volume-risk relationship or any other function can also be accommodated albeit at the expense of more cumbersome algebra. In the literature on stochastic models of cancer it is common to model v(t), and h(t) by implication, as a parametric function where some parameters could be random. In this paper we target a non-parametric specification with the aim to make the tumor growth pattern h(t) data-driven. We consider h(t) non-random. The above considerations are meant to justify the statistical assumptions behind (2.1) as a working mechanistic model. However, we are not insisting on the above deep mechanistic interpretation, and will use the working model as a way to loosely interpret the baseline hazard as some surrogate of the dynamic pattern of cancer growth. Its non-parametric data-driven nature makes deeper modeling not essential for the purposes of this paper.
Following Kimmel and Flehinger (1991) , Ghosh (2006) considers two special cases: Case I: tumors are detected immediately when the metastases occur, μ → ∞; Case II: metastases do not affect the time to diagnosis, μ = 1. In the following we discuss how they relate to traditional analysis methods. 
Since e −(θ+η)H = G, Case I is a competing risks model where the cause-specific potential times U ∼ θ h and T * ∼ ηh come from the same proportional hazards (PHs) family. Common h across all causespecific hazards (CSHs) means that the likelihood will not factorize into independently parameterized cause-specific terms, and an efficiency gain is expected comparing with methods that focus on one specific cause (U ) and treat T * as nuisance (censoring). Generally, two non-parametric functions of time (infinite dimensional parameters) can be identified by mapping to the joint distribution of observed data expressed by the sub-distribution pdf f (t, S * = 1) and f (t, S * = 0). (Such mapping is represented by a system of two integro-differential equations with modelbased f (t, S * = 1) and f (t, S * = 0) on the left and their true counterparts on the right, respectively). This means that the PH assumption in the competing risks model of Case I can be relaxed by endowing U and T * each with its own non-parametrically specified hazard function. Treating U ∼ ηh 0 as time to failure and T * ∼ θ h as time to censoring, we can consider data (T = min(T * , U ), S * ) as right censored with S * being the censoring index (1 = failure, 0 = censoring), the distribution of censoring being parameterized independently and not contributing any information on h 0
Case II: Independence of recurrence and metastases. Independence between U and T * leads to μ = 1 under model (2.1),
This corresponds to current status r.v. U (status-generating variable) with a hazard function ηh, observed at random times T * ∼ θ h, i.e., the status-generating variable and the random observation time belong to the same PH family. Processing data generated under (2.6) by conventional current status data analysis that treats T as independently parameterized nuisance will result in loss of efficiency.
Similar to Case I, we can relax the PH assumption and consider current status data with hazards of U and T * as parameterized independently
While the special cases considered above connect to approaches used in the literature to estimate the unobserved onset of metastases (Kimmel and Flehinger, 1991; Ghosh, 2006) , the assumptions of independence or immediate diagnosis may be unrealistic.
While we can relax the PH assumption in special cases, it is difficult to do this in general. Indeed, when one considers metastatic process as parameterized independently from the primary tumor, three non-parametric hazards would have to be defined: one for onset of the metastatic process at time U , one for T * while the tumor is localized, and one for the metastatic recurrence. As we noted earlier, at most two non-parametric functions can be identified from the data.
ESTIMATION
Likelihood
Let V * be the censoring time which is independent of (T * , S * ), given Z ; τ be the maximum followup time in the study such that τ = inf {t : pr(T
. . , n are n independent and identically distributed replicates of (T * , S * , V * , Z ), such that the observed time-to-event marked data for subject i = 1, . . . , n consist of (Jacobsen, 2006) .
We define the filtration as
. . , n, s = 0, 1}, and consider the continuous (orthogonal) case where no two counting processes can jump simultaneously and Z i is predictable. Under independent censoring, we have Pr[dN
is the differential over the time argument of the mark-specific cumulative hazard corresponding to (2.3), given covariates Z i .
Our model is semiparametric in the sense that the baseline cumulative hazard H (·) is unspecified and is treated as a non-decreasing step function with jumps {dH } at the times where events are observed. The full parameter set is = (β, H (·)), where β is finite-dimensional and H (·) is infinite-dimensional. Estimation procedures for our joint model are developed using a set of ideas recently used for transformation models. We rely on the Weighted Breslow Estimator algorithm (Chen, 2009 ) that reduces likelihood maximization to a set of recurrent score equations that are similar to the computationally efficient martingale estimating equations (Chen and others, 2002) . Alternatively, we could use EM algorithm of Tsodikov (2003) . Consistency proof is based on empirical processes (Zeng and Lin, 2007; Kosorok, 2008) . Weak convergence is based on the martingale structure of the score equations elucidated by Chen (2009) .
Non-parametric maximum likelihood estimation
Our goal is to estimate β and H jointly. This is done using the profile likelihood approach. The profile likelihood is defined as maximized over H when β is held out and fixed. This is accomplished by a Breslow-type iterative estimator (see below) that implicitly defines an estimator for the hazardĤ (t, β) that depends on β. By replacing H in the likelihood (β, H ) with dĤ (t, β) we obtain the profile likelihood
The estimate ofβ is obtained by maximizing the profile likelihood. Finally,ˆ = (β,Ĥ (t,β)) gives the solution to the joint estimation problem. Construct the following orthogonal martingales based on the observed marked counting processes with respect to a filtration
Denote the partial derivatives of s i (H ; β) with respect to its H and β arguments as:
In Section D of supplementary material, for any functional J (H ), we define a local functional derivative ∂ J (H )/∂ dH (t) at the timepoint t and apply it to the likelihood (3.1) to derive a score equation for the infinite-dimensional parameter H : U H (t) = 0, uniformly over t. The score equation can be expressed as a Breslow-type estimator satisfyinĝ
3)
Using common scientific computing software, it is now feasible to solve the large-scale problem (3.1) directly. However, a structured solution is more stable and computationally attractive. We note that the weights ω can be obtained by setting all weights (3.4) to 1. The EE approach provides estimators that are consistent, computationally fast, yet not fully efficient. Asymptotic properties of the EE estimators are established using martingale theory (see Section E.2 of supplementary material). The efficiency of the NPMLE is due to the fact that optimal weights depend on martingale residuals evaluated over the future of t. The computational convenience of fixed weights can be exploited in an iterative reweighted algorithm representing a variation on the Weighted Breslow approach of Chen (2009) By replacing dH (t) and H (t) in the loglikelihood (3.1) by the point of convergence dĤ (t) andĤ (t) of the above procedure, we obtain the profile likelihood pr (β) = (β, {dĤ }). Asymptotic properties of the resultant NPMLE estimator are established in Section E.3 of supplementary material using martingale theory and empirical processes.
EXAMPLES AND SIMULATION STUDIES
Simulation studies
To assess the finite-sample properties of the parameter estimates obtained by the proposed methodology, we perform a series of Monte Carlo simulation studies under different scenarios, including increasing and decreasing hazards (See Section F of supplementary material). Based on the simulation results, both proposed estimation and inference procedures using unweighted and weighted Breslow-type estimators perform well with diminishing bias as sample sizes increases, and coverage probability at 95% nominal level. When sample size is small, the weighted Breslow-type estimator based method has slightly better performance than the inefficient EE approach, with slightly better coverage probability and agreement between empirical standard errors and asymptotic standard deviations. As the sample size increases, the efficiency loss from inefficient estimators is almost negligible. This makes the estimating equations approach attractive as it is faster than the NPMLE. We also used simulations to compare our approach to other approaches applicable to the same data as discussed in Section 2.2. Following Ghosh (2006) , Kimmel and Flehinger (1991) , for case-only data (only recurrences are included), we continue to focus on the following special cases. Case I is when cancers are detected immediately when the metastasis occurs (2.4). In this case the observed data are treated as rightcensored time to metastases where the mark is interpreted as a censoring index. Case II is when cancer detection is not affected by the presence of metastases (2.6). In this case we can treat the observed data as a current-status (interval-censored) observation on time to metastases with the mark indicating whether the time is right-or left-censored. We also consider a CSH PH model with separate baseline hazards for each cause that can accommodate full data including censoring.
Methods used for comparison include (1) the proposed joint model; (2) interval-censored PH model; (3) CSH Cox PH model. In order to put all special cases and associated methods on equal footing, we removed censoring from the experiments. Simulated data are thus generated under the proposed model with different μ. In addition to μ = ∞ (Case I) and μ = 1 (Case II), we also consider a realistic scenario where the hazard ratio for the effect of the occurrence of metastasis on the risk of recurrence is μ = exp(1) = 2.71. Note that the interval-censored and right-censored PH models are only able to provide valid inferences on η, the covariate effects on the latent metastatic process U , under the respective special cases. Table 1 presents results under a realistic scenario (μ = exp(1) = 2.72). Only the proposed method yields unbiased estimates, and all other approaches provide biased results since they assume a different relationship between the latent metastatic process and cancer detection. The simulation results assuming that Case I or Case II is true are given in Section G of supplementary material, and are summarized below.
Under Case I (μ = ∞, immediate diagnosis of metastases), we observe unbiased estimation from our proposed method and the CSH Cox PH model. The proposed method is most efficient among the unbiased models. This is because the CSH Cox PH model assumes different baseline hazard functions for S = 0 and 1, while the proposed approach applies a common-H joint model to all types of failure. Under Case II (μ = 1, independence) both the proposed method and the interval-censored method (for η only) provide unbiased estimates. However, the interval-censored method is less efficient than the proposed method, because it ignores the information retained in the time-to-detection (recurrence), while in the proposed approach times to recurrence and metastases are linked by a common parameter H and a joint inference procedure.
Breast cancer adjuvant therapy
We apply the proposed method to a multi-center randomized clinical trial of early breast cancers in Canada diagnosed from 1992 to 2000 (Fyles and others, 2004; Pintilie, 2006) . This study is designed to compare the effect of tamoxifen alone (Tam) with irradiation plus tamoxifen (RT + Tam) as adjuvant therapy for breast-conserving surgery on disease-free survival (DFS) and local relapse among women of 50 years of age or older with T1 or T2 node-negative breast cancers. The details of the data are presented in Section H of supplementary material. The covariates included in the following regression analysis are: treatment arm (RT + Tam vs. Tam, Z 1 ), hormone-receptor status (positive vs. negative, Z 2 ), age at cancer first diagnosis ( 60 vs. 50-59, Z 3 ), and tumor size (< 2 cm vs. 2 cm reference, Z 4 ). Figures 1 and 2 show DFS curves and recurrence-site-specific cumulative incidences. They reveal interesting patterns of disease natural history under different treatment options. While RT + Tam significantly reduced the incidences of local and overall recurrence, higher incidence of distant recurrence in RT + Tam group was observed. Multivariate Cox PH model further suggests RT + Ram(logHR = −0.51, p = 0.006), positive hormone-receptor (logHR = −0.75, p = 0.005) and < 2 cm tumor (logHR = −0.73, p < 0.001) were associated with prolonged DFS, while age of diagnosis over 60 only nominally decreased DFS risk ( p = 0.125).
The two commonly used competing risks analysis methods, CSH PH model (Kalbfleisch and Prentice, 2002, Chapter 8) and subdistribution hazard (SDH) PH model (Fine and Gray, 1999) are also used, and the results are summarized in Table 2 . The differences between the two approaches have been discussed extensively (e.g., Dignam and others, 2012 and reference therein) . Model choice depends on the questions of interest and interpretations. In this study both methods give similar results showing a reduction (Gray, 1988). in local recurrence and no evidence of any effect on the risk of metastases. Increased observed incidence of metastatic recurrences would then be interpreted as a consequence of a reduction in competition for this type of failure. However, the competing risks models do not address the specific risk dependence resulting from local tumor being the source of metastases. When one factors this into account, other things unchanged, a reduction in local tumor growth should lead to lower rates of shedding metastases by the local tumor. The unaltered potential risk of metastases under the circumstances is an indication of increased metastatic activity, despite reduced local growth. Unlike our proposed approach, the competing risks PH models leave us without an inferential instrument to assess this hypothesis.
Our proposed approach (Model (2.1)) offers an explicit interpretation (Table 2) . We continue to observe the beneficial therapy effect on local recurrence ( p < 0.001). Meanwhile, our model suggests that under RT + Tam, the onset of detectable metastases occurs sooner ( p < 0.001), and exerts a stronger acceleration effect on time to detection of distant recurrence compared to Tam alone ( p < 0.001). We also observe an increased risk of onset of metastases for older patients ( p = 0.013), which may explain why being older was not associated with DFS while older age had a beneficial effect on local recurrence (not shown). Based on the results from our proposed method, multiple biological hypotheses may be generated that call for further validation studies. It is possible that in addition to cell killing effect prolonging the period to local recurrence, RT + Tam stimulates dormant metastatic cells to come out of their niche to a state where they would be sensitive to Tamoxifen. It might also be the case that RT + Tam makes metastases surface sooner (for whatever other reason) while they are still treatable. These considerations would explain why, despite the splash of metastatic growth activity significant in this analysis, the literature still reports improved survival rates in adjuvant Tamoxifen settings (Ragaz and Coldman, 1998) .
PREDICTIONS
An important benefit of the mechanistic model is that it is capable of making predictions of the onset of detectable metastases, given the information observed on the subject. Such predictions are important not only as a way to generate more information about the patient's disease, but also as a modeling tool for downstream events such as cancer-specific survival, where the point of metastatic onset may be an important but a missing covariate. Since the onset of metastases is never observed directly, at any given prediction point t, it is left of t if a metastatic recurrence is observed, right of t if a non-metastatic recurrence is observed, and left or right of t in the absence of recurrence. Derived in Section B of supplementary material are the predicted distributional characteristics under different information about the subject available at t. Specifically, we have the following conditional survival functions of the time to onset of detectable metastases U :
Non-metastatic recurrence: G(u|T
Metastatic recurrence: G(u|T
No recurrence yet:
Shown in Figure 3 are the predicted survival functions (5.3) and (5.2) under varying event time t for a subject over 60 diagnosed with positive hormone-receptor status and tumor less than 2 cm in size. In both situations, the longer it takes to observe an event on the subject, the more favorable the distribution of the time to onset of metastases. This is a consequence of estimated positive correlation between occurrence of metastases and the risk of recurrence. A longer time to recurrence therefore selects for a less aggressive metastatic process, regardless of the type of recurrence that is held constant. However, the predicted curves under distant recurrence (medians, etc.) suggest that the age of metastases (delay between onset and recurrence) increases with t that might be an adverse factor. It is an intriguing question which of these In the case of observed distant recurrence at t, metastases cannot occur after t. In the case of no observed recurrence at t, metastases can occur before or after t. latent predicted features are important determinants of cancer-specific survival and treatment success, and we will pursue elsewhere in this regard.
CONCLUSION AND DISCUSSION
In this paper, we have presented a general framework to analyze time-to-event marked endpoints in cancer studies using a semiparametric mechanistic regression model. By viewing the observed marked endpoints as cross-sectional observations of latent disease natural history, we aim to understand the disease progression and its relationship with observed data and covariates (e.g., treatment interventions and prognostic factors). Existing approaches provide neither explicit description nor the relevant inference for the relationship between the latent disease progression process and the observed phenotype process. At the same time devising the structure of this relationship may bring clinically and biologically important information to decision makers. Our model provides clinically meaningful dependence measures for the survival time and mark variables, and an opportunity to predict unobserved progression events. We seek to exploit the power of a joint model of both the event time and the mark by viewing them together as a manifestation of the same disease.
The methodology of this paper is applicable to a non-binary mark S * = S(T * ). In general, one can consider a stochastic process S(t) and a related process U (t) = e β θ Z (t)+β μ S(t) whose distribution is parameterized by the scalar dependence parameter β μ , the tumor growth functional parameter H , and regression coefficients β θ . The marginal survival function G(t) for T * will then represent a Laplace functional L(H [0, t]) = E{e − t 0 U (x) dH (x) } of the process U evaluated at the function H . The properties of such transforms could be exploited to derive relevant model quantities and the NPMLEĤ that will retain its form except that summation over the mark variable s will turn into an integral over ds, and S w 0 will have a different form. This extension could be used to study biomarkers of disease progression measured at diagnosis, and to provide a prediction for the unmeasured part of the trajectory of the biomarker for the patient that may be useful in the design of surveillance interventions and individualized treatments.
If the PH assumption between latent progression and observed recurrence is violated, estimates will be biased. The assumption can be relaxed without modifying the general line of the paper by assuming that the baseline hazards in λ U and λ T * are linked by a transformation model. Specifically, a simple model λ T * = h exp(α) θμ S can be used to test the PH assumption as the hypothesis α = 0. Also, using martingale properties of the score functions (Section E.3.1 of supplementary material), one could diagnose general model violations using cumulative martingale residuals plots. Alternatively, a formal diagnostic theory could be developed along the lines of Chen and others (2012) .
We developed two estimation procedures based on ideas previously proposed for a different class of models. One is based on EEs motivated by martingale property, and the other one is a non-parametric maximum likelihood estimator (NPMLE). Asymptotic properties of both estimators are established and finite sample properties are studied by Monte Carlo simulations. While the EE-based estimator is not fully efficient, we did not observe much efficiency loss compared to NPMLE when the sample size is large.
Our framework offers a range of possible extensions for models used in event history analysis. Depending on the disease natural history of interest and the observed data, different multistate latent structures can be used to explain a more complex mark. For example, progression in stage and grade of cancer could be incorporated.
The survival component could be extended to multivariate data, for example, jointly modeling recurrence and cancer death. The proposed approach provides a key instrument for building joint models of downstream events, as the risk of those events can be regressed on features of the latent processes naturally incorporated into the mechanistic model. A simpler initial approach could be to use some predicted quantities of the latent process as covariates in the survival model. For example, the expected delay in diagnosis of metastases (age of the metastatic tumor), given an observed recurrence on the patient (Section 5), could be an important predictor explaining the heterogeneity of the patients survival commonly observed in cancer studies.
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